86270-03-3Relevant articles and documents
Pharmaceutical-Oriented Methoxylation of Aryl C(sp 2)-H Bonds using Copper Catalysts
Zhang, Guofu,Zhu, Jianfei,Tong, Chaolai,Ding, Chengrong
supporting information, p. 1451 - 1454 (2018/05/14)
A pharmaceutical-oriented, copper(II)-catalyzed methoxylation of aryl C(sp 2)-H bonds has been developed. This simple and environmentally benign reaction system occurs efficiently using oxygen as oxidant with broad substrate scope and high functional group tolerance.
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer
Zhang, Chun-Hui,Chen, Kai,Jiao, Yan,Li, Lin-Li,Li, Ya-Ping,Zhang, Rong-Jie,Zheng, Ming-Wu,Zhong, Lei,Huang, Shen-Zhen,Song, Chun-Li,Lin, Wan-Ting,Yang, Jiao,Xiang, Rong,Peng, Bing,Han, Jun-Hong,Lu, Guang-Wen,Wei, Yu-Quan,Yang, Sheng-Yong
supporting information, p. 9788 - 9805 (2016/11/19)
Herein we report the sophisticated process of structural optimization toward a previously disclosed Src inhibitor, compound 1, which showed high potency in the treatment of triple negative breast cancer (TNBC) both in vitro and in vivo but had considerable toxicity. A series of 3-(phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine derivatives were synthesized. In vitro cell-based phenotypic screening together with in vivo assays and structure-activity relationship (SAR) studies finally led to the discovery of N-(3-((4-amino-1-(trans-4-hydroxycyclohexyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)ethynyl)-4-methylphenyl)-4-methyl-3-(trifluoromethyl)benzamide (13an). 13an is a multikinase inhibitor, which potently inhibited Src (IC50 = 0.003 μM), KDR (IC50 = 0.032 μM), and several kinases involved in the MAPK signal transduction. This compound showed potent anti-TNBC activities both in vitro and in vivo, and good pharmacokinetic properties and low toxicity. Mechanisms of action of anti-TNBC were also investigated. Collectively, the data obtained in this study indicate that 13an could be a promising drug candidate for the treatment of TNBC and hence merits further studies.
Enantiodifferentiating photoisomerization of cyclooctene included and sensitized by benzoate modified β-cyclodextrin derivatives: Switching of product chirality by solvent
Li, Guangxun,Wang, Zhizhong,Lu, Runhua,Tang, Zhuo
scheme or table, p. 3097 - 3101 (2011/06/26)
Solvent effect upon asymmetric photosensitization has been investigated in the enantiodifferentiating photoisomerization of cyclooctene(1Z), sensitized by benzoate modified β-cyclodextrin derivatives bearing nitrogen, oxygen or sulfur substituents. The enantiomeric excess (ee) and E/Z ratio of reaction products were susceptible to the concentration of methanol in the aqueous solution, which could switch to the chirality of product unprecedentedly. Further investigation indicated that the conformation of the modified CDs in aqueous methanol solutions with 1Z were highly sensitive to both the substituent(s) on benzoate moiety of the modified CDs and the concentration of methanol. Solvent content represents a new versatile tool to efficiently manipulate the asymmetric photochemical reactions, in which the chirality of products can be switched by simply changing the methanol content of reaction solvent rather than synthesizing the antipodal sensitizers.
